Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies

Chimeric Antigen Receptor T (CAR-T) cells are certainly an important therapy for patients with relapsed and/or refractory hematologic malignancies. Currently, there are five CAR-T cell products approved by the FDA but several research groups and/or biopharmaceutical companies are encouraged to devel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rodrigo Nalio Ramos, Virginia Picanço-Castro, Theo Gremen M. Oliveira, Alfredo Mendrone, Junior, Gil Cunha De Santis, Martin Hernan Bonamino, Vanderson Rocha
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	New technologies CAR cell therapies Manufacturing Gene delivery Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/558a6b96477e4bcba2af415589f2cdde
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:558a6b96477e4bcba2af415589f2cdde
record_format	dspace
spelling	oai:doaj.org-article:558a6b96477e4bcba2af415589f2cdde2021-11-18T04:51:04ZAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies2531-137910.1016/j.htct.2021.09.007https://doaj.org/article/558a6b96477e4bcba2af415589f2cdde2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921001413https://doaj.org/toc/2531-1379Chimeric Antigen Receptor T (CAR-T) cells are certainly an important therapy for patients with relapsed and/or refractory hematologic malignancies. Currently, there are five CAR-T cell products approved by the FDA but several research groups and/or biopharmaceutical companies are encouraged to develop new products based on CAR cells using T or other cell types. Production of CAR cells requires intensive work from the basic, pre-clinical to translational levels, aiming to overcome technical difficulties and failure in the production. At least five key common steps are needed for the manipulation of T-lymphocytes (or other cells), such as: cell type selection, activation, gene delivery, cell expansion and final product formulation. However, reproducible manufacturing of high-quality clinical-grade CAR cell products is still required to apply this technology to a greater number of patients. This chapter will discuss the present and future development of new CAR designs that are safer and more effective to improve this therapy, achieving more selective killing of malignant cells and less toxicity to be applied in the clinical setting.Rodrigo Nalio RamosVirginia Picanço-CastroTheo Gremen M. OliveiraAlfredo Mendrone, JuniorGil Cunha De SantisMartin Hernan BonaminoVanderson RochaElsevierarticleNew technologiesCAR cell therapiesManufacturingGene deliveryDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S46-S53 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	New technologies CAR cell therapies Manufacturing Gene delivery Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	New technologies CAR cell therapies Manufacturing Gene delivery Diseases of the blood and blood-forming organs RC633-647.5 Rodrigo Nalio Ramos Virginia Picanço-Castro Theo Gremen M. Oliveira Alfredo Mendrone, Junior Gil Cunha De Santis Martin Hernan Bonamino Vanderson Rocha Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
description	Chimeric Antigen Receptor T (CAR-T) cells are certainly an important therapy for patients with relapsed and/or refractory hematologic malignancies. Currently, there are five CAR-T cell products approved by the FDA but several research groups and/or biopharmaceutical companies are encouraged to develop new products based on CAR cells using T or other cell types. Production of CAR cells requires intensive work from the basic, pre-clinical to translational levels, aiming to overcome technical difficulties and failure in the production. At least five key common steps are needed for the manipulation of T-lymphocytes (or other cells), such as: cell type selection, activation, gene delivery, cell expansion and final product formulation. However, reproducible manufacturing of high-quality clinical-grade CAR cell products is still required to apply this technology to a greater number of patients. This chapter will discuss the present and future development of new CAR designs that are safer and more effective to improve this therapy, achieving more selective killing of malignant cells and less toxicity to be applied in the clinical setting.
format	article
author	Rodrigo Nalio Ramos Virginia Picanço-Castro Theo Gremen M. Oliveira Alfredo Mendrone, Junior Gil Cunha De Santis Martin Hernan Bonamino Vanderson Rocha
author_facet	Rodrigo Nalio Ramos Virginia Picanço-Castro Theo Gremen M. Oliveira Alfredo Mendrone, Junior Gil Cunha De Santis Martin Hernan Bonamino Vanderson Rocha
author_sort	Rodrigo Nalio Ramos
title	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
title_short	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
title_full	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
title_fullStr	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
title_full_unstemmed	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies
title_sort	associação brasileira de hematologia, hemoterapia e terapia celular consensus on genetically modified cells. vii. present and future of technologies for production of car cell therapies
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/558a6b96477e4bcba2af415589f2cdde
work_keys_str_mv	AT rodrigonalioramos associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviipresentandfutureoftechnologiesforproductionofcarcelltherapies AT virginiapicancocastro associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviipresentandfutureoftechnologiesforproductionofcarcelltherapies AT theogremenmoliveira associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviipresentandfutureoftechnologiesforproductionofcarcelltherapies AT alfredomendronejunior associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviipresentandfutureoftechnologiesforproductionofcarcelltherapies AT gilcunhadesantis associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviipresentandfutureoftechnologiesforproductionofcarcelltherapies AT martinhernanbonamino associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviipresentandfutureoftechnologiesforproductionofcarcelltherapies AT vandersonrocha associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviipresentandfutureoftechnologiesforproductionofcarcelltherapies
_version_	1718424973147635712

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies

Ejemplares similares